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ABSTRACT
Objectives: This study investigated the long-term effects
of bosentan, an oral endothelin ETA/ETB receptor
antagonist, in patients with pulmonary arterial hyperten-
sion (PAH) exclusively related to connective tissue
diseases (CTD).
Methods: A total of 53 patients with PAH related to
connective tissue diseases (PAH–CTD) in World Health
Organization (WHO) functional class III received bosentan
62.5 mg twice a day for 4 weeks and then 125 mg twice
a day for 44 weeks in this open non-comparative study.
Assessments at weeks 16 and 48 included WHO class,
clinical worsening, quality of life (Short-Form Health
Survey (SF-36) and health assessment questionnaire
(HAQ) modified for scleroderma), and survival (week 48
only). Safety and tolerability were monitored throughout
the study.
Results: At week 48, WHO class improved in 27% of
patients (95% CI 16–42%) and worsened in 16% (95% CI
7–29%). Kaplan–Meier estimates were 68% (95% CI 55–
82%) for absence of clinical worsening and 92% (95% CI
85–100%) for survival. Overall changes in quality of life
were minimal. There were no unexpected side effects
observed during the study.
Conclusions: In most patients, bosentan was associated
with improvement or stability of clinical status. The 92%
estimate for survival at 48 weeks is a significant
achievement in this patient population.
Pulmonary arterial hypertension (PAH) is a pro-
gressive and often fatal complication of connective
tissue diseases (CTDs) such as systemic sclerosis
(SSc), systemic lupus erythaematosus (SLE), and
overlap or mixed connective tissue disease
(MCTD).
1–3 CTDs are disorders characterised by a
wide range of vascular, inflammatory, and fibrotic
manifestations in many organs including lung,
kidney, and skin. Over the past decade, advances in
medical treatment have improved the management
of the complications associated with CTDs.
Patients with SLE have benefited from immuno-
suppressive treatments,
4 while improved manage-
ment of the specific complications associated with
SSc and MCTD (eg, scleroderma renal crisis), has
improved prognosis.
5 However, PAH remains a
major cause of long-term morbidity and mortality.
The reported symptomatic PAH prevalence mea-
sured by right heart catheterisation is 8–12% in
patients with SSc,
166–11% in patients with SLE,
78
and up to 10–45% in patients with MCTD
3 as
measured by echocardiography and/or right heart
catheterisation.
In these patients, early detection of PAH and a
multidisciplinary approach to diagnosis and treat-
ment in specialised PAH and/or CTD centres may
improve clinical outcome.
91 0Therapeutic approaches
for PAH–CTD are based on those used for treating
idiopathic PAH (iPAH).
11 Anticoagulation, diuretics,
andoxygensupplementationareoftenusedalthough
the benefit of this supportive therapy has not been
demonstrated in PAH–CTD.
1 Prostacyclin analogues
may improve exercise capacity and pulmonary
haemodynamics in these patients.
12–15 However,
despite treatment, patients with PAH–CTDs are
functionally impaired with a decreased health status
and a poor prognosis. In the absence of concomitant
PAH, survival of patients with SSc exceeds 90% at 1
year
16 17 but once PAH has been diagnosed, it
decreasesto50%,
18 19whichisworsethanforpatients
with iPAH (84%).
19 The risk of death from PAH
related to SSc is threefold higher than from iPAH.
19
Bosentan is an oral dual (ETA and ETB)
endothelin-1 receptor antagonist. In placebo-con-
trolled clinical trials and in long-term extension
studies,
20–22 bosentan was well tolerated, improved
exercise capacity and haemodynamics, and delayed
the time to clinical worsening in patients with
iPAH and PAH–CTD. Survival estimates at 1 and 2
years were 86% and 73%, respectively, in a
subgroup analysis of patients with PAH–CTD.
23
Improvement in quality of life (SF-36 instrument)
has been reported after 3 and 6 months of
bosentan treatment in patients with iPAH and
PAH–CTD (59% and 41%, respectively) participat-
ing in the VITAL study.
24 However, changes in
health-related quality of life have not been assessed
together with survival. Since the concomitant
assessment of these two aspects is critical to
appreciate overall outcome, the present multi-
centre European study was designed to investigate
changes in health-related quality of life together
with survival over a 48-week observation period in
patients with PAH exclusively related to CTD.
PATIENTS AND METHODS
Patients
Included patients (over 18 years of age) had PAH in
World Health Organization (WHO) functional
class III
25 related to diffuse or limited SSc,
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confirmed in all patients by right heart catheterisation requiring
mean pulmonary artery pressure >25 mmHg at rest, pulmon-
ary vascular resistance .3 Wood units, and pulmonary capillary
wedge pressure ,15 mmHg.
26 This catheterisation was per-
formed within 6 months prior to the start of bosentan therapy.
Signs of right heart failure, if present at baseline, were required
to be stable and patients were required to have received
adequate diuretics treatment prior to bosentan initiation.
Total lung capacity (TLC) was required to be above 50% of
predicted, to exclude patients with severe interstitial lung
disease. Patients were also excluded if they had received any
PAH treatments (except anticoagulants) within 1 month of
screening, if they were receiving or were expected to receive
epoprostrenol or prostacyclin analogues for more than 2
consecutive weeks, or if they had received glibenclamide,
cyclosporin A, or tacrolimus within 1 week of screening.
Selective phosphodiesterase inhibitors and endothelin receptor
antagonists other than bosentan were not allowed during the
study. Disease-modifying antirheumatic drugs (DMARDs) were
allowed provided the patient had been stable on treatment for
3 months prior to bosentan initiation.
The study was conducted according to the most recent
amendments to the Declaration of Helsinki, and in adherence to
Good Clinical Practice guidelines. Local institutional review
boards or independent ethics committees approved the protocol.
Written informed consent was obtained from all patients.
Study design and procedures
The study was a prospective single-arm trial and was conducted
in 23 centres in 8 European countries. Patients received
bosentan 62.5 mg twice a day for 4 weeks followed by the
125 mg twice a day target dose for 44 weeks, in addition to
stable antirheumatic treatment. Patients who did not tolerate
the 125 mg twice a day target dose were down titrated to the
starting dose.
Patients were evaluated on an outpatient basis at baseline and
at weeks 4, 8, 16, 24, 36, and 48 or at premature withdrawal.
Efficacy assessments included the change from baseline to
weeks 16 and 48 in WHO functional class, the time from
baseline to clinical worsening (defined as the combined end-
point of death or hospitalisation due to PAH complications, use
of epoprostenol or prostacyclin analogues for worsening of
PAH, lung transplantation, discontinuation due to worsening of
PAH), and the time to death.
Health-related quality of life and disability were evaluated at
baseline and week 48, with a generic instrument (the Medical
Outcomes Study 36-Item Short-Form Health Survey (SF-36))
27
and a disease-specific instrument (the scleroderma modified
Health Assessment Questionnaire (HAQ)).
28 Both instruments
have been validated in a variety of chronic diseases including
SSc
28–32 and SLE.
33 34
In the SF-36 questionnaire, 35 items cover 8 domains of
health: physical functioning, role limitation caused by physical
functioning, bodily pain, general health perceptions, vitality,
social functioning, role limitation caused by emotional pro-
blems, and mental health. The patient’s responses are first
reported on a scale from 0 to 100 (higher score indicates better
health-related quality of life) for each domain following item
weighing and additive scaling, these eight scale scores (0–100)
are finally transformed (using a linear z-score transformation)
to correspond to a mean of 50 and standard deviation of 10 in
the 1998 general US population (norm-based scale scores). A
36th item (health transition) asks respondents about any health
changes over the past year using five assessment categories,
‘‘much better’’ (category 1), ‘‘somewhat better’’ (category 2),
‘‘about the same’’ (category 3), ‘‘somewhat worse’’ (category 4),
and ‘‘much worse’’ (category 5).
The HAQ assessment includes 20 questions in 8 domains of
functional activities: dressing, rising, eating, walking, hygiene,
reach, grip, and usual activities. The patient’s responses are
reported on an ordinal scale from 0 (no disability) to 3 (complete
disability). The HAQ disability index is the average score across
the eight domains. In addition, six visual analogue scales (VAS)
evaluate disease-specific organ system symptoms: pain, digital
ulcer, gastrointestinal, vascular, and pulmonary involvement,
and overall disease severity, with scores standardised to a
continuous scale from 0 (no symptoms) to 3 (worst symptoms).
Safety was assessed by the reporting of adverse events up to
1 day after study drug discontinuation and serious adverse
events up to 28 days after study drug discontinuation. Liver
function tests were performed at monthly intervals. Any
marked laboratory abnormality was reported as an adverse
event.
Statistical methods
Sample size selection was empirical for this open, single arm
study. Statistical analyses were performed in an exploratory
fashion. For numerical endpoints, the change from baseline is
presented with 95% two-sided confidence intervals, based on
asymptotic normality assumption. For dichotomous endpoints,
the proportion of patients is provided with 95% two-sided CI,
based on the binomial exact distribution. For time-to-event
Table 1 Demographics and patient characteristics at baseline
Parameter Value
Male/female, n (%) 9 (17%)/44 (83%)
Age, years (mean (SD)) 63 (13) (range 22–79)
Weight, kg (mean (SD)) 67 (13) (range 40–99)
Caucasian/Asian 51 (96%)/2 (4%)
Aetiology, n (%):
Limited systemic sclerosis 29 (55%)
Diffuse systemic sclerosis 13 (25%)
Mixed connective tissue disease 6 (11%)
Systemic lupus erythaematosus 5 (9%)
Time from CTD diagnosis, weeks (mean (SD)) 431 (503) (range 0–2227)
Time from PAH diagnosis, weeks (mean (SD)) 45 (66) (range 1–236)
Signs of right heart failure, n (%) 8 (15%)
Patients with at least one digital ulcer, n (%) (n=50) 15 (30%)
Right heart catheterisation:
Mean pulmonary arterial pressure, mmHg
(mean (SD))
39.5 (12.6)
Cardiac index, litres/min/m
2 (mean (SD); n=49) 2.9 (0.9)
Mean pulmonary capillary wedge pressure, mmHg
(mean (SD); n=51)
10.1 (4.4)
Pulmonary vascular resistance, dyn/s/cm
–5
(mean (SD); n=47)
559.4 (371.5)
Total lung capacity, % (mean (SD); n=46) 80.8 (18.3)
Forced vital capacity, % of predicted (mean (SD)) 85.9 (23.6)
Concomitant treatment, n (%):
Antithrombotic agents* 41 (77%)
Antacids/drug for treatment of peptic ulcer and
flatulence
40 (75%)
Calcium channel blockers 32 (60%)
Corticosteroids{ 30 (57%)
Diuretics 28 (53%)
Unless otherwise stated, n=53.
*Mostly acenocoumarol, warfarin, or acetylsalicylic acid. {Mostly prednisolone.
CTD, connective tissue disease; PAH, pulmonary arterial hypertension.
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two-sided CI calculated from Greenwood’s formula. All treated
patients were used for the survival analysis.
Values for missing assessments of WHO functional class,
SF-36, and HAQ/VAS were derived by carrying forward the last
observed post-baseline assessment. For patients who died,
underwent lung transplantation, or discontinued study medica-
tion due to worsening of PAH prior to the considered timepoint
(week 16 or week 48), the most conservative approach was used
in case of missing assessment. The missing assessment was
replaced with the worst value out of: (1) the last available post-
baseline value observed for this patient, or (2) the worst value
observed at the considered timepoint (ie, week 16 or week 48)
over all other patients.
RESULTS
A total of 53 patients were treated over a 1-year period and
received bosentan from July 2003 to August 2005. The median
exposure to bosentan was 48.6 weeks (range 0.7 to 56.7 weeks).
During the study, 17 patients (32%) were prematurely
discontinued from study treatment because of an adverse event
(n=14, 26%), sudden death (n=1, 2%), disease progression
(n=1, 2%), or loss to follow-up (n=1, 2%). In total, 36
patients out of 53 completed the study.
Patient demographics and disease characteristics
Patient demographics and disease characteristics are presented
in table 1. The majority of patients were female and the mean
(SD) age was 63 (13) years. Of 53 patients, 42 had SSc, 29
patients had limited and 13 patients had diffuse SSc. There were
six patients with MCTD and five with SLE. Twelve patients
had a history or evidence of lung fibrosis at baseline. In all but
one of these cases was FVC greater than 60% of predicted.
Concomitant corticosteroid therapy
The numbers (percentages) of patients treated with prednisone
or prednisolone included: 7 (54%) patients with diffuse SSc
(mean dose: 12.4 mg; range: 5–40 mg); 12 (41%) patients with
limited SSc (mean dose: 10.0 mg; range: 2.5–40 mg); 2 (40%)
patients with SLE (mean dose: 11.3 mg, range: 5–30 mg); and
6 (100%) patients with MCTD (mean dose: 9.1 mg, range:
2.5–25 mg).
WHO functional class
All patients were in WHO functional class III at baseline. At
week 16, WHO class improved in 12 out of 51 patients (24%),
remained stable in 35 patients (69%), and worsened in 4
patients (8%). At week 48, it improved in 14 out of 51 patients
(27%), remained stable in 29 patients (57%), and worsened in 8
patients (16%) (fig 1).
Clinical worsening
Summary statistics on clinical worsening are shown in fig 2.
The Kaplan–Meier estimate for the absence of clinical worsen-
ing was 88% at week 16 and 68% at week 48. Interestingly,
there was no clinical worsening among the five patients with
SLE at week 48 whereas the estimate for the absence of clinical
worsening was 75%, 67%, and 61% for the patients with diffuse
SSc, MCTD, and limited SSc, respectively. One patient received
intravenous epoprostenol for 10 days during the course of the
study.
Figure 1 Improvement/worsening in World Health Organization (WHO)
functional class at week 16 and week 48. Two patients at week 16 and
three at week 48 were discontinued because of pulmonary arterial
hypertension (PAH) worsening/death and were assigned WHO functional
class IV at week 16 and week 48, respectively, as per protocol. (n=51).
Confidence intervals (95%) are indicated in brackets.
Figure 2 Kaplan–Meier estimates for time to clinical worsening,
defined as the combined endpoint of death, hospitalisation due to
pulmonary arterial hypertension (PAH) complications, use of
epoprostenol or prostacyclin analogues for worsening of PAH, lung
transplantation, or discontinuation due to worsening of PAH. The Kaplan–
Meier estimate was 88% (95% CI 79–97%) at week 16, and 68% (95% CI
55–82%) at week 48.
Figure 3 Kaplan–Meier estimates of survival (deaths occurring after
treatment discontinuation for an adverse event were counted as an
event). The Kaplan–Meier estimate was 92% (95% CI 85–100%) at
week 48.
Extended report
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The Kaplan–Meier estimates for the observed survival are
presented in fig 3. Survival was 92% at week 48. Four deaths
were reported during the study: (1) sudden death, (2)
staphylococcal sepsis as a result of ischemic colitis, (3)
hyponatremia as a complication of high dose diuretics, including
furosemide, and (4) exacerbated dyspnoea from worsening
pulmonary fibrosis. These four patients had been diagnosed
with limited SSc (n=2), diffuse SSc (n=1), and MCTD
(n=1). No patient with SLE died during the study.
SF-36 and HAQ/VAS scores
The SF-36 domain scores decreased minimally from baseline to
week 48. The self-evaluated health transition item at week 48
showed slightly more patients reporting improvement than
patients reporting deterioration, in contrast to the baseline
status. Accordingly, change in mean (SEM) value for this item
was –0.83 (0.22) (95% CI –1.27 to –0.39) (table 2). The HAQ
scores presented an overall increase at week 48 (table 3). The
disability index was 1.17 (0.11) at baseline and tended to
increase at week 48 (0.22 (0.11)). A similar mean increase was
reported for all VAS scores at week 48, except for the lung score,
which was stable on average (table 3).
Safety
The most frequent adverse events (% patients) observed during
the study were peripheral oedema (17%), liver enzyme eleva-
tions (17%, of which 11% were specified as aminotransferase
Table 2 Changes from baseline to week 48 in the Short Form Health Survey (SF-36) domain scores and
health transition item
Baseline Week 48 Change 95% CI
Domain scores (norm-based)
Physical functioning* 28.76 (1.24) 27.72 (1.48) –1.04 (1.37) –3.79 to 1.71
Role, physical* 27.47 (2.15) 26.19 (1.89) –1.28 (2.25) –5.81 to 3.25
Pain 43.00 (1.55) 41.92 (1.74) –1.08 (1.60) –4.29 to 2.14
General health perception* 33.89 (1.24) 32.42 (1.24) –1.47 (1.35) –4.19 to 1.25
Vitality* 40.63 (1.41) 40.15 (1.47) –0.49 (1.32) –3.15 to 2.17
Social functioning 39.67 (1.81) 38.51 (2.13) –1.16 (2.26) –5.70 to 3.38
Role, emotional{ 32.73 (3.03) 30.65 (3.10) –2.07 (3.65) –9.43 to 5.29
Mental health* 45.11 (1.65) 42.94 (1.98) –2.17 (1.63) –5.45 to 1.11
Health transition item 3.81 (0.15) 2.98 (0.18) –0.83 (0.22) –1.27 to –0.39
Health transition item (n)
1: Much better 3 4
2: Somewhat better 2 17
3: About the same 6 9
4: Somewhat worse 26 10
5: Much worse 10 7
Values are mean (SEM). Four patients were discontinued because of pulmonary arterial hypertension (PAH) worsening/death and
were assigned the worst value observed over the analysis set at week 48, as per protocol. The health transition item is reporting
comparison to 1 year before. A decrease (negative change) in a domain score corresponds to deterioration.
n=47, *n=46, {n=45.
Table 3 Changes from baseline to week 48 in the Health Assessment Questionnaire (HAQ) and visual
analogue scale (VAS) scores on a 0–3 scale
Baseline Week 48 Change 95% CI
HAQ scores
Dressing 1.15 (0.16) 1.49 (0.19) 0.34 (0.16) 0.01 to 0.67
Arising 0.77 (0.13) 1.09 (0.17) 0.32 (0.20) –0.08 to 0.72
Eating 0.81 (0.13) 0.98 (0.17) 0.17 (0.16) –0.16 to 0.50
Walking 1.32 (0.14) 1.60 (0.18) 0.28 (0.16) –0.05 to 0.60
Hygiene 0.98 (0.15) 1.30 (0.19) 0.32 (0.18) –0.04 to 0.68
Reach 1.28 (0.16) 1.62 (0.18) 0.34 (0.16) 0.01 to 0.67
Grip 1.15 (0.17) 1.28 (0.18) 0.13 (0.17) –0.22 to 0.48
Activity 1.94 (0.14) 1.98 (0.17) 0.04 (0.14) –0.23 to 0.32
HAQ disability index 1.17 (0.11) 1.39 (0.14) 0.22 (0.11) –0.01 to 0.44
VAS scores
Pain 0.87 (0.11) 1.06 (0.13) 0.19 (0.16) –0.13 to 0.51
Gastrointestinal 0.44 (0.10) 0.67 (0.11) 0.23 (0.11) 0.0 to 0.46
Lung 1.71 (0.11) 1.70 (0.14) –0.02 (0.14) –0.29 to 0.26
Vascular 1.11 (0.13) 1.32 (0.15) 0.21 (0.19) –0.18 to 0.60
Digital ulcer 0.58 (0.12) 0.86 (0.16) 0.28 (0.16) –0.03 to 0.59
Disease 1.39 (0.13) 1.56 (0.14) 0.17 (0.13) –0.10 to 0.44
Values are mean (SEM), n=47. Five patients were discontinued because of pulmonary arterial hypertension (PAH) worsening/
death and were assigned the worst value observed over the analysis set at week 48, as per protocol. A negative change
corresponds to an improvement of the HAQ and VAS scores.
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nausea (13%).
At least one serious adverse event was reported in 45% of
patients (37 events in 24 patients). The most frequent serious
adverse events were exacerbated dyspnoea (8%) and pneumonia
(8%). All serious adverse events were judged unrelated to study
medication by the investigators.
Overall, 14 patients (26%) discontinued study medication
because of an adverse event or serious adverse event.
Discontinuations most often involved exacerbated dyspnoea
(6%), general physical health deterioration (6%), and liver
enzyme increase (6%).
DISCUSSION
This is the first large multi-centre prospective single-arm study
of survival and quality of life in PAH–CTD confirmed by right
heart catheterisation. The results represent an important source
of data on survival and quality of life in patients with PAH–
CTD treated with bosentan.
The survival estimate of 92% with only slight alteration in
the patients’ quality of life can be considered as a positive
outcome in PAH–CTD, a progressive disease with very poor
outcome in the absence of specific therapy. Treatment of PAH
with bosentan was indicated in the patients included in this
study. Hence, a placebo therapy for 48 weeks would have been
unethical. The absence of a placebo group may be considered a
limitation of the study, with concern that some of the
improvements were due to ‘‘placebo’’ effect, rather than drug
efficacy. However, non-subjective parameters, such as survival,
cannot be explained by a placebo effect. Previously reported
placebo-controlled PAH studies of bosentan or other
PAH-specific treatments have not shown any clinically relevant
improvements in placebo groups, in fact, they have generally
shown a decline.
13 14 20 21 35–37 In addition, a historical comparison
shows that the observed estimate for absence of clinical
worsening at week 16 is similar to the rates reported for the
PAH–CTD patients treated with bosentan in the placebo-
controlled BREATHE-1 study.
21
The survival results of the study are in line with published
data in patients treated with bosentan. In particular, the
observed survival rate of 92% is comparable with the 1-year
survival of 86% reported by Denton et al
23 in a subgroup analysis
of 64 patients with PAH–CTD (SSc, SLE, MCTD), who were
enrolled in the two bosentan placebo-controlled PAH trials and
the open-label extensions. Similarly, Williams et al
38 reported a
survival at 1 year of 81% in a cohort of 45 patients with
PAH related to SSc in class III–IV who were treated with
bosentan as first line therapy. In contrast, the survival
reported by these authors for the historical control (47 patients
treated with basic therapy with (n=27) or without (n=20)
prostanoids) was 68%.
38 Data on the effects of injectable
prostanoids and sildenafil on haemodynamics, exercise
capacity and symptoms in PAH associated with connective
tissue disease have been presented.
39 40 However, their effect
has not been studied in a specific long-term cohort in this
patient population.
41 42
The results of the study also suggest that bosentan improved
or stabilised the clinical status of most patients with PAH–
CTD. In 84% of patients, the WHO functional class improved
(27%), or remained unchanged (57%) at week 48.
The self-evaluated SF-36 health transition item showed more
improvements than deteriorations in overall health perception
at the end of the study, as well as an improvement in this
overall perception compared to the year preceding the study.
The decrease in SF-36 domain scores was lower than that
generally considered as the minimal clinically important
difference.
43 The apparent discrepancy between the encouraging
results of the SF-36 health transition item and the decrease in
the domain scores can be explained by the different nature of
these measures. Whereas the health transition item is a general
and relative (compared to 1 year ago) measure, the domain
scores are specific and absolute (providing a value at the date of
assessment) measures.
Patients included in the current study had moderate-to-severe
baseline disabilities
44 (HAQ disability index =1.17 (0.11)). At
week 48, the observed mean increases in the HAQ disability
index (+0.22, 95% CI –0.01 to 0.44) reached the minimal clinical
important difference value reported for patients with SSc (0.10–
0.22)
45 46 and the VAS scores increased by less than 0.3 units,
except for the lung score which was stable. Interpretation of
these findings is limited by the absence of a control group. In a
different cohort of SSc patients without PAH followed for a
mean of 1.8 years, the HAQ disability index increased by 0.4
units and VAS scores by 0.5–0.6 despite state of the art
therapy.
47 Hence, our findings suggest that bosentan PAH
therapy was specifically associated with a stabilisation of the
lung score despite other coexisting CTD respiratory manifesta-
tions, but, as expected, had less impact on other organ-related
quality of life indicators.
As for any instrument, the HAQ/VAS and SF-36 tools have
well known limitations: the patients’ judgments about the
extent of their disabilities may show marked individual
variation,
48 the HAQ/VAS does not capture the psychological
distress felt by patients with PAH and/or CTDs,
49 50 and neither
instrument is specific for PAH. Consequently, they may have
limited sensitivity in detecting changes in quality of life
resulting from PAH treatment over time.
51 New instruments,
which were not available at the start of this study, such as the
Cambridge Pulmonary Hypertension Outcome Review
(CAMPHOR)
51 have been developed from qualitative, unstruc-
tured interviews with PAH patients and are expected to provide
a more accurate assessment of the impact of PAH on quality of
life, when validated translations permit their use in interna-
tional studies.
The minimum TLC for inclusion in our study was 50% of
predicted. Low TLC may reflect interstitial lung disease or chest
wall restriction or other cause for low lung volumes such as
pleural disease. There was evidence of lung fibrosis in some
cases but our experience and previously published data
52 53
suggest that outcome is especially poor in CTD cases,
particularly SSc, in which there is RHC proven pulmonary
hypertension together with lung fibrosis. Hence, the inclusion
of these patients would be more likely to have had a negative
impact on the overall prognosis in the cohort.
In conclusion, our study suggests that patients with PAH–
CTD can be treated with bosentan in centres having PAH in
addition to CTD expertise and that bosentan is effective for
the treatment of this patient population. Our results
suggest that bosentan improves or stabilises the clinical
status in the majority of PAH–CTD patients and, most
importantly, has a positive impact on survival. In contrast
to the observed changes of SF-36 and HAQ scores not related
to PAH, the HAQ lung VAS score stabilised and the SF-36
health transition item improved. Altogether, these results
are consistent with sustained benefit in this patient popula-
tion, which is usually characterised by a high morbidity
and mortality.
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